Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended			2 Months Ended
	Aug. 31, 2021	Apr. 30, 2021	Jul. 31, 2020	Nov. 30, 2020	Mar. 31, 2022	Dec. 31, 2021	Aug. 10, 2021	Jul. 31, 2021	Jul. 30, 2021
Preferred stock, shares issued (in shares)					0	0			16,944,484
Preferred stock par value (in dollars per share)					$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)					109,675,173	111,251,660			150,000,000
Common stock, shares authorized (in shares)					1,000,000,000	1,000,000,000		150,000,000
Preferred stock, shares authorized (in shares)					10,000,000	10,000,000
Minimum [Member]
Common stock, shares authorized (in shares)	150,000,000	19,000,000
Maximum [Member]
Common stock, shares authorized (in shares)	1,000,000,000	23,251,555
IPO [Member]
Undesignated preferred stock capital shares reserved for future issuance							10,000,000
Convertible preferred stock outstanding converted into common stock	84,722,420
IPO [Member] | Minimum [Member]
Common stock, shares authorized (in shares)							150,000,000
IPO [Member] | Maximum [Member]
Common stock, shares authorized (in shares)							1,000,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued (in shares)			6,237,500
Preferred stock par value (in dollars per share)			$ 8.00
Proceeds from issuance of preferred stock			$ 49.9
Payments of stock issuance costs			$ 0.2
Shares issued, Fair value					$ 40.0
Series A Preferred Stock [Member] | Adimab Assignment Agreement [Member]
Preferred stock, shares issued (in shares)			5,000,000
Series B Preferred Stock [Member]
Preferred stock, shares issued (in shares)				1,410,434
Preferred stock par value (in dollars per share)				$ 56.72
Proceeds from issuance of preferred stock				$ 80.0
Payments of stock issuance costs				$ 0.2
Series B Preferred Stock [Member] | Adimab Assignment Agreement [Member]
Preferred stock, shares issued (in shares)				44,076
Shares issued, Fair value				$ 2.5
Series C Preferred Stock [Member]
Preferred stock, shares issued (in shares)		4,296,550
Preferred stock par value (in dollars per share)		$ 78.08578
Proceeds from issuance of preferred stock		$ 335.5
Payments of stock issuance costs		$ 0.3
Preferred stock original issue and conversion price, per share					$ 78.08578
Preferred stock, shares authorized (in shares)		4,296,550
Series C Preferred Stock [Member] | Adimab Assignment Agreement [Member]
Preferred stock, shares issued (in shares)		128,064
Shares issued, Fair value		$ 10.0